^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

fingolimod

i
Other names: FTY 720, TDI-132, FTY-720, FTY720
Company:
Generic mfg.
Drug class:
S1P receptor modulator
4d
Phase 2 Study of Fingolimod in Lung Cancers (clinicaltrials.gov)
P2, N=38, Not yet recruiting, Medical University of South Carolina | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: May 2026 --> Nov 2026
Trial completion date • Trial primary completion date
|
fingolimod
1m
Trial initiation date
|
fingolimod
2ms
SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade. (PubMed, Cell Death Dis)
Here, we unveil the clinical relevance of SPHK1 in bladder cancer progression and the driver role in bladder cancer metastasis. Moreover, we demonstrated the inhibitory effect of FDA-approved SPHK1 inhibitor FTY720 on bladder cancer metastasis from both in vitro and in vivo models.
Journal
|
PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • SPHK1 (Sphingosine Kinase 1)
|
fingolimod
3ms
Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway. (PubMed, J Integr Neurosci)
Fingolimod was found to reduce ischemic brain injury in a dose-dependent manner. Moreover, it was also found to alleviate inflammation following ischemic brain injury via the HMGB1/TLR4/NF‑κB signaling pathway.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta)
|
fingolimod
3ms
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt (clinicaltrials.gov)
P=N/A, N=30, Completed, Hikma Pharmaceuticals LLC | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Nov 2023
Trial completion • Trial completion date
|
IFNB1 (Interferon Beta 1)
|
fingolimod
3ms
FTY720/Fingolimod mitigates paclitaxel-induced Sparcl1-driven neuropathic pain and breast cancer progression. (PubMed, FASEB J)
Furthermore, in this TNBC mouse model that mimics human breast cancer, FTY720 administration also enhanced the anti-tumor effects of paclitaxel, leading to reduced tumor progression and lung metastasis. Taken together, our findings suggest that targeting the S1P/S1PR1 axis with FTY720 is a multipronged approach that holds promise as a therapeutic strategy for alleviating both CIPN and enhancing the efficacy of chemotherapy in TNBC treatment.
Journal
|
FAP (Fibroblast activation protein, alpha) • GFAP (Glial Fibrillary Acidic Protein) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
paclitaxel • fingolimod
4ms
DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial primary completion date: Apr 2030 --> Jul 2027
Trial primary completion date
|
Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
4ms
T cell interactions with microglia in immune-inflammatory processes of ischemic stroke. (PubMed, Neural Regen Res)
Clinical trials have been conducted on the ways to modulate the interactions between T cells and microglia toward anti-inflammatory communication using the immunosuppressant fingolimod or overdosing with Treg cells to promote neural tissue repair and reduce the damage caused by ischemic stroke...In the future, a key research direction for ischemic stroke treatment could be rooted in the enhancement of anti-inflammatory factor secretion by promoting the generation of Th2 and Treg cells, along with the activation of M2-type microglia. These approaches may alleviate neuroinflammation and facilitate the repair of neural tissues.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • BDNF (Brain Derived Neurotrophic Factor)
|
fingolimod
5ms
Cryptococcosis Associated With Biologic Therapy: A Narrative Review. (PubMed, Open Forum Infect Dis)
Clinicians should remain vigilant for the risk of cryptococcosis in patients receiving biologics that affect the Th1/macrophage activation pathways, such as tumor necrosis factor α antagonists, Bruton tyrosine kinase inhibitors, fingolimod, JAK/STAT inhibitors (Janus kinase/signal transducer and activator of transcription), and monoclonal antibody against CD52. Other risk factors-such as age, underlying condition, and concurrent immunosuppressants, especially corticosteroids-should also be taken into account during risk stratification.
Review • Journal
|
CD52 (CD52 Molecule)
|
fingolimod
5ms
FITCH: Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage (clinicaltrials.gov)
P1, N=28, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
Trial completion
|
fingolimod
5ms
Enrollment change • Head-to-Head
|
fingolimod
6ms
SPRING: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov)
P4, N=30, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
fingolimod
6ms
Study of Fingolimod (clinicaltrials.gov)
P2, N=38, Not yet recruiting, Medical University of South Carolina
New P2 trial
|
fingolimod
7ms
DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
P4, N=800, Active, not recruiting, The Cleveland Clinic | Recruiting --> Active, not recruiting
Enrollment closed
|
Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
7ms
NEOS: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov)
P3, N=180, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2029 --> Dec 2031 | Trial primary completion date: Aug 2026 --> Mar 2027
Trial completion date • Trial primary completion date • Head-to-Head
|
fingolimod
9ms
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt (clinicaltrials.gov)
P=N/A, N=30, Active, not recruiting, Hikma Pharmaceuticals LLC | Trial completion date: Oct 2023 --> May 2024
Trial completion date
|
IFNB1 (Interferon Beta 1)
|
fingolimod
10ms
Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses. (PubMed, Proc Natl Acad Sci U S A)
Last, analyses of proteomic databases of MS samples identified Ana peptides to be more abundant in the cerebrospinal fluid (CSF) of human MS patients with high disease activity. A role for Ana in MS as a consequence of a lack of astrocytic TIMP-1 production could influence both the efficacy of fingolimod responses and innate remyelination potential in the MS brain.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
KIM1 expression • TIMP1 expression
|
fingolimod
11ms
Pharmacological Effects of FTY720 and its Derivatives. (PubMed, Curr Top Med Chem)
At present, a series of FTY720 derivatives, which have pharmacological effects such as anti-tumor and alleviating airway hyperresponsiveness, have been developed through structural modification. This article reviews the pharmacological effects of FTY720 and its derivatives.
Journal
|
SPHK1 (Sphingosine Kinase 1)
|
fingolimod
12ms
FITCH: Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting | N=10 --> 28 | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
fingolimod
1year
Trial completion date
|
fingolimod • Ocrevus (ocrelizumab)
1year
Enrollment change
|
fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
1year
Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models. (PubMed, Cancers (Basel))
These results suggest that the efficacy of Fingolimod is dependent on the glioblastoma tumor microenvironment. Globally, our data suggest that the response to Temozolomide varies depending on the cancer model, consistent with its clinical activity, whereas the potential activity of Fingolimod may merit further evaluation.
Preclinical • Journal
|
temozolomide • fingolimod
1year
A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells. (PubMed, Oncol Res)
CM2-II-173 exhibited a more potent effect on the invasiveness of MDA-MB-231 TNBC cells compared to FTY720. Taken together, this study demonstrated that CM2-II-173 has the potential to be a lead compound that can inhibit cancer progression of not only TNBC cells, but also of liver, prostate, and ovarian cancer cells.
Journal
|
MMP9 (Matrix metallopeptidase 9)
|
fingolimod
1year
Inhibitory Effect of Fingolimod on Head and Neck Squamous Cell Carcinoma and Its Mechanism: Gene Set Enrichment Analysis. (PubMed, Cell Mol Biol (Noisy-le-grand))
Fingolimod can promote the arrest in G0/G1 of SCC9 cells, and PLK1 is a key targeted gene for the treatment of HNSC. Fingolimod can inhibit cell proliferation caused by PLK1 over-expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PLK1 (Polo Like Kinase 1)
|
BCL2 expression • PLK1 overexpression
|
fingolimod
over1year
Inhibition of AGEs-RAGE-PP2A Axis Alleviates Cognitive Impairment after Chronic Heart Failure. (PubMed, Cell Mol Biol (Noisy-le-grand))
Mice were divided into six groups: Sham, TAC, Sham+RAGE-/-, TAC+RAGE-/-, AG, and FTY720 group...Deficient of AGEs, RAGE and activating PP2A can significantly attenuate the cognitive impairment in CHF mice, and protect the brain structure. This mechanism seems via reducing the expression of Aβ, p-tau, and apoptotic protein.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression
|
fingolimod
over1year
Trial completion
|
paclitaxel • fingolimod
over1year
Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Report and Literature Review. (PubMed, Neurol India)
There are a few reports of melanoma as a side effect of Fingolimod in the literature. Herein we aim to report a known case of multiple sclerosis under Fingolimod presenting with persistent nasal congestion who was eventually diagnosed with soft palate malignant melanoma.
Review • Adverse events
|
fingolimod
over1year
Brain resident memory T cells rapidly expand and initiate neuroinflammatory responses following CNS viral infection. (PubMed, Brain Behav Immun)
These neuroinflammatory events were induced by TRMs, as depletion of peripheral T cells or blocking T cell trafficking using FTY720 did not change the neuroinflammatory course...The use of cognate antigen to reactivate CD8 TRMs enables us to isolate the neuropathologic effects induced by this cell type independently of other immune cells, differentiating this work from studies employing whole pathogen re-challenge. This study also demonstrates the capacity for CD8 TRMs to contribute to pathology associated with neurodegenerative disorders and long-term complications associated with viral infections.
Journal
|
CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • ITGAE (Integrin Subunit Alpha E)
|
fingolimod
over1year
Nanovaccines Fostering Tertiary Lymphoid Structure to Attack Mimicry Nasopharyngeal Carcinoma. (PubMed, ACS Nano)
Furthermore, the intratumoral effector memory T cells (Tem), CD45, CD3, CD8, CD44, and CD62L, did not decrease after blocking the egress of T cells from tumor-draining lymph nodes by FTY-720. These results demonstrated that the nanovaccine can foster TLS formation, which thus enhances local immune responses significantly, delays tumor outgrowth, and prolongs the median survival time of murine models of mimicry nasopharyngeal carcinoma, demonstrating a promising strategy for nanovaccine development.
Journal
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL19 (C-C Motif Chemokine Ligand 19)
|
fingolimod
over1year
Mucosal vaccination with an adenoviral vector vaccine protects against pulmonary breast cancer metastasis by robust induction of tissue-resident memory T-cells in the lung (P421) (IMMUNOLOGY 2023)
By using FTY720 to inhibit T-cell circulation upon tumor challenge, we confirmed that TRM are crucial contributors to the vaccine efficacy. In conclusion, induction of tumor-antigen specific lung TRM are a key point in local protection against pulmonary metastasis. Ongoing studies analyze the therapeutic use of this vaccination strategy as well as its potential in combination with immune checkpoint inhibition.
Viral vector
|
CD69 (CD69 Molecule) • ITGAE (Integrin Subunit Alpha E) • IL1B (Interleukin 1, beta)
|
fingolimod
over1year
Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia. (PubMed, Mol Cell Proteomics)
Accordingly, proliferation assays revealed that KIT mutant FDC-P1 cells were more sensitive to the DNA-PK inhibitors M3814 or NU7441, compared with empty vector controls. DNA-PK inhibition combined with inhibition of KIT signaling using the kinase inhibitors dasatinib or ibrutinib, or the protein phosphatase 2A activators FTY720 or AAL(S), led to synergistic cell death...Combined dasatinib and M3814 treatment also synergistically inhibited phosphorylation of the transcriptional regulators MYC and MYB. This study provides insight into the oncogenic pathways regulated by DNA-PK beyond its canonical role in DNA repair, and demonstrates that DNA-PK is a promising therapeutic target for KIT mutant cancers.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
FLT3 mutation • KIT mutation • KIT D816V • KIT V560G
|
dasatinib • Imbruvica (ibrutinib) • fingolimod • peposertib (M3814) • NU7441
over1year
Modulation of blood-brain tumor barrier for delivery of magnetic hyperthermia to brain cancer. (PubMed, J Control Release)
BBTB modulation is achieved by targeted delivering fingolimod to brain tumor region via dual redox responsive PCL-SeSe-PEG (poly (ε-caprolactone)-diselenium-poly (ethylene glycol)) polymeric nanocarrier...As a result, the co-delivery of heat shock protein 70 inhibitor VER-155008 with ZnCoFe NCs could realize synergistic magnetic hyperthermia effects upon exposure to an alternating current magnetic field (ACMF) in both GL261 and U87 brain tumor models. This modulation approach brings new ideas for the treatment of central nervous system diseases that require delivery of therapeutic agents across the blood-brain barrier (BBB).
Journal
|
S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
fingolimod
over1year
A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer. (PubMed, Pharmaceutics)
In vivo PET imaging showed significantly higher accumulation (2.1 ± 0.3 %ID/g; p = 0.02) of [Ga]Ga-DOTA-PEG-TZ(PEG-Octr)-PEG-Trz-PEG-Val-Cit-pABOC-FTY720 in SSTR2 prostate cancer xenografts than in the SSTR2 xenografts (1.5 ± 0.4 %ID/g) at 13 min post-injection (p.i.) with a rapid excretion through the kidneys. Taken together, these proof-of-concept results validate the design concept of the T-SMPDC, which may hold a great potential for targeted diagnosis and therapy of NEPC.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SPHK1 (Sphingosine Kinase 1)
|
fingolimod
almost2years
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. (PubMed, Sci Transl Med)
D2C7-IT+αCD40 treatment stimulated intratumoral CD8 T cell proliferation and generated cures in glioma-bearing mice despite FTY720-induced peripheral T cell sequestration. To determine potential translation, immunohistochemistry staining confirmed CD40 expression in human GBM tissue sections. These promising preclinical data allowed us to initiate a phase 1 study with D2C7-IT+αhCD40 in patients with malignant glioma (NCT04547777) to further evaluate this treatment in humans.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • CD40 (CD40 Molecule)
|
EGFR mutation • EGFR wild-type • CD40 expression
|
fingolimod • D2C7
almost2years
Transplanted human iPSC-derived vascular endothelial cells promote functional recovery by recruitment of regulatory T cells to ischemic white matter in the brain. (PubMed, J Neuroinflammation)
iVEC transplantation suppresses neuroinflammation, but suppression of neuroinflammation per se does not promote remyelination. Recruitment of Tregs by transplanted iVECs contributes significantly to promotion of remyelination in the injured white matter.
Journal
|
CD4 (CD4 Molecule)
|
fingolimod
almost2years
Effect of Quercetin and Fingolimod, Alone or in Combination, on the Sphingolipid Metabolism in HepG2 Cells. (PubMed, Int J Mol Sci)
Studies on the effect of quercetin and fingolimod on the two proteins associated with apoptotic events, AKT and Bcl-2, showed that only quercetin, alone or in combination, down-regulated the activity of the two proteins. The reported observations provide information which can be useful in the search of novel anti-tumor approaches, aiming at optimization of the therapeutic effect and maximal preservation of healthy tissues.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
fingolimod